GEMIO Technologies, Inc.
|Executive Summary:||GEMIO Technologies has developed next generation ion source technology that will enable mass spectrometry to move from an instrument in specialized biochemical labs to an everyday tool for predictive and personalized medicine in clinics and hospitals. GEMIO believes that its innovation has the promise of creating a step-function to a multi-billion dollar market for predictive molecular diagnostics tools and personalized medicine.
Mass spectrometry (MS) has become the prevalent tool in molecular diagnostics. The power of mass spectrometry stems from the fact that the very accurate measurement of the mass of a molecule allows the determination of its chemical identity. This ability is the basis for biomarker discovery, development of diagnostic tests (e.g. for detection of diseases such as cancer or Alzheimer), drug discovery, measurement of drug effectiveness, and studies of metabolism. However, since mass spectrometers utilize electromagnetic fields for such measurements, the technique depends on the ability to ionize biomolecules (i.e. give them a net electric charge). Therefore, ion sources for biomolecules are the most important component of any MS. |